Clinical Trial Search

Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…

Primary: Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA — 170; 157…

Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants

Primary: The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority) — 188; 241 Patients — p=<0.001

Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: Composite of All-cause Mortality, Stroke and Bleeding — 60; 64 Participants

Primary: Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism…

Primary: Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period — 55; 56 Participants

Primary: Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding — 18.04; 16.42 Events per 100 patient-years…

Primary: Interview Process — 34 Participants

Primary: First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per…

Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006

Primary: Bleeding Events — 18; 8; 22; 17 Participants

Primary: Incidence of All Bleeding — 20.3; 23.8; 29.3 percentage of subjects with bleeds

Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001

Primary: The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist…

Primary: Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode — 2.02; 10.1; 10.5; 14.6 Number of Patients per 100 Patient years — p=0.035

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: Adjudicated Incidence of Bleeding Events — 5.5; 12.7; 7.3; 18.3 percent of subjects with outcome event — p=.367

Primary: Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only — 3; 1; 1; 3 events

Primary: First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication — 963; 963; 136; 123 participants — p=0.8570

Primary: Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex — 115; 77; 30; 46 Participants

Primary: Number of Participants With a Safety Event — 2; 0 Participants

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Number of Patients With Clinically-Significant Bleeding — 14; 17 Participants

Primary: Description of the Characteristics of Anticoagulant Initiators — 3.41; 4.30; 3.59; 3.82 Scores on a scale

Primary: Frequency (Percentage) of Participants With Adverse Drug Reactions — 28.2 Percentage of participants

Primary: Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period — 159; 173…

Primary: Incidence of Any Adjudicated Bleeding Events — 20.0; 22.7; 23.8 percentage of subjects with bleeds